| Abstrakt: |
Competing Interests: Conflict-of-Interest Disclosures: Amy Abernethy reports personal fees from Verily/Alphabet, relationships with Georgiamune and EQRx, and personal investments in Iterative Health and One Health, outside the submitted work. Atul J. Butte reports support for the present manuscript from National Institutes of Health; grants or contracts from Merck, Genentech, Peraton (as a prime for an NIH contract), Priscilla Chan and Mark Zuckerberg, the Bakar Family Foundation; royalties or licenses from NuMedii, Personalis, and Progenity; consulting fees from Samsung, Gerson Lehman Group, Dartmouth, Gladstone Institute, Boston Children’s Hospital, and the Mango Tree Corporation; payment of honoraria from Boston Children’s Hospital, Johns Hopkins University, Endocrine Society, Alliance for Academic Internal Medicine, Roche, Children’s Hospital of Philadelphia, University of Pittsburgh Medical Center, Cleveland Clinic, University of Utah, Society of Toxicology, Mayo Clinic, Pfi zer, Cerner, Johnson and Johnson, and the Transplantation Society; payment for expert testimony from Foresight, support for attending meetings and/or travel from Alliance for Academic Internal Medicine, Cleveland Clinic, University of Utah, Society of Toxicology, Mayo Clinic, Children’s Hospital of Philadelphia, American Association of Clinical Chemistry, Analytical, and Life Science & Diagnostics Association; patents planned, issued, or pending from Personalis, NuMedii, Carmenta, Progenity, Stanford, and University of California, San Francisco; participation on a Data Safety Monitoring Board or Advisory Board from Washington University in Saint Louis, Regenstrief Institute, Geisinger, and University of Michigan; leadership or fi duciary role in other board, society, committee or advocacy group, from National Institutes of Health, National Academy of Medicine, and JAMA; and stock or stock options from Sophia Genetics, All-birds, Coursera, Digital Ocean, Rivian, Invitae, Editas Medicine, Pacifi c Biosciences, Snowfl ake, Meta, Alphabet, 10x Genomics, Snap, Regeneron, Doximity, Netfl ix, Illumina, Royalty Pharma, Starbucks, Sutro Biopharma, Pfi zer, Biontech, Advanced Micro Devices, Amazon, Microsoft, Moderna, Tesla, Apple, Personalis, and Lilly. Juan Enriquez reports investments with Excel Venture Management, outside the submitted work; investments in various life science technologies, including leading-edge brain technologies, and co-authoring a book on the impact of emerging brain technologies.Bob Kocher reports being a Partner at the venture capital fi rm Venrock which invests in technology and healthcare businesses. Dr. Kocher is also on the board of Premera Blue Cross. Venrock is not currently an investor in any neuromodulation or neurotechnology companies. Sarah H. Lisanby reports grants from NIMH, outside the submitted work; a patent on electrical and magnetic brain stimulation therapy systems held by the NIH and Columbia University issued. Jacob S. Sherkow reports employment with University of Illinois, grants from National Institutes of Health, personal fees from Expert Consulting services, outside the submitted work. |
